What Brightstar Lottery (BRSL)'s 19-Year Lotterywest Technology Deal Means For Shareholders

• Earlier this week, Brightstar Lottery PLC announced that its subsidiaries signed a 19-year contract with Lotterywest to supply a new central gaming system, 775 retailer terminals, and a full digital offering for Western Australia’s lottery operations.
• Beyond the technology win, Brightstar committed to long-term local job creation, university scholarships, and broader digital capability-building in Western Australia, deepening its role as an embedded partner rather than just an infrastructure vendor.
• We’ll now examine how winning this long-duration Lotterywest technology contract could reshape Brightstar Lottery’s investment narrative and long-term outlook.

AI is about to change healthcare. These 29 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Brightstar Lottery Investment Narrative Recap

To own Brightstar Lottery, you need to believe that long-term lottery technology contracts and digital adoption can translate into steadier earnings from a still-volatile, jackpot-sensitive business. The 19-year Lotterywest win supports the long-term contract-life and digital channels catalyst, but it does little to reduce near term exposure to regulatory shifts or soft jackpot cycles, which remain the key swing factors for the stock.

The recent expansion of Brightstar’s patented Cash Pop game to Pennsylvania, its 17th U.S. state, sits squarely in the same story as Lotterywest: scaling proprietary content and daily play formats that can deepen digital engagement. Together, these developments speak directly to the core catalyst of shifting the mix toward higher-margin digital games while trying to offset competition from new forms of online entertainment.

Yet despite the contract win and product rollouts, increasing regulatory scrutiny in key markets remains a risk investors should be aware of, especially if...

Read the full narrative on Brightstar Lottery (it's free!)

Brightstar Lottery's narrative projects $2.6 billion revenue and $295.9 million earnings by 2028. This requires 2.5% yearly revenue growth and a $462.9 million earnings increase from $-167.0 million.

Uncover how Brightstar Lottery's forecasts yield a $20.17 fair value, a 25% upside to its current price.

Exploring Other Perspectives

Two fair value estimates from the Simply Wall St Community span a wide range of US$10.54 to US$20.17, underlining how far apart individual views can be. Against that backdrop, the Lotterywest contract and growing digital footprint highlight how contract wins can support the long revenue visibility that some investors are banking on, even as regulatory and jackpot related risks keep others cautious, so it is worth comparing several perspectives before making up your mind.

Explore 2 other fair value estimates on Brightstar Lottery - why the stock might be worth as much as 25% more than the current price!

Build Your Own Brightstar Lottery Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Brightstar Lottery research is our analysis highlighting 1 key reward and 1 important warning sign that could impact your investment decision.
• Our free Brightstar Lottery research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Brightstar Lottery's overall financial health at a glance.

Want Some Alternatives?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.
• Uncover the next big thing with financially sound penny stocks that balance risk and reward.
• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com